期刊文献+

Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents on interleukin-1β-induced coronary artery in-stent restenosis in pigs 被引量:6

Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents on interleukin-1β-induced coronary artery in-stent restenosis in pigs
原文传递
导出
摘要 Background Coronary artery in-stent restenosis (ISR) and late stent thrombosis remain as important complications of stenting. The inflammation reactions to sirolimus and paclitaxel-eluting stents were investigated in a swine stenosis model induced by interleukin (IL)-1β.Methods Mini pigs (n=12; 2-3 months old and weighing 25-30 kg) were subjected to thoracotomy. Segments (10 mm)of the mid left anterior descending coronary artery and left circumflex coronary artery were exposed and aseptically wrapped with a cotton mesh soaked with IL-1β (5 μg). After 2 weeks, the animals were anesthetized and quantitative coronary arteriography (QCA) was performed. The stenosis sites were randomized into three groups for stent insertion: a sirolimus-eluting stent (SES) group (FirebirdTM, n=7), a paclitaxel-eluting stent (PES) group (TAXUSTM, n=9), and a bare-metal stent (BMS) group (YINYITM, Dalian Yinyi Biomaterials Development Co., Ltd, China, n=8). The three different stents were randomly implanted into stenosis segments. Expression of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-α), P-selectin and vascular cell adhesion molecule-1 (VCAM-1) was determined by reverse transcription-coupled polymerase chain reaction (RT-PCR).Results QCA showed severe stenosis in IL-1β treated segments. The SES and PES groups showed lower 1-month angiographic late lumen loss (LLL) within the stent and the lesion compared with BMS (P 〈0.05) by follow-up QCA. The SES showed lower LLL than that of PES in reducing 1-month inflammation lesions in pigs by follow-up QCA ((0.15±0.06)mm vs. (0.33±0.01) mm, P 〈0.0001). The neointimal hyperplasia areas in SES and PES showed lower than those of BMS (SES (11.6±1.7) mm2, PES (27.2±1.6) mm2 vs. BMS (76.2±1.3) mm2, P 〈0.0001). The mRNA expression of MCP-1 by RT-PCR in SES and PES showed lower than that of BMS at 30 days after stenting (SES 0.20±0.03, PES 0.48±0.49 vs.BMS 0.58±0.07, P 〈0.05). Levels of VCAM-1 in SES were significantly lower than those of PES and BMS (SES 0.35±0.08 vs. PES 0.65±0.13, BMS 0.70±0.06, P 〈0.05). Histochemical immunostaining of vessel walls showed lower inflammatory chemokine MCP-1 expression in the SES and PES groups compared with BMS.Conclusion SESs were superior in reducing 1-month angiographic LLL in inflammation lesions in pigs, strongly suggesting that SESs can suppress inflammatory reactions in ISR at multiple points. Background Coronary artery in-stent restenosis (ISR) and late stent thrombosis remain as important complications of stenting. The inflammation reactions to sirolimus and paclitaxel-eluting stents were investigated in a swine stenosis model induced by interleukin (IL)-1β.Methods Mini pigs (n=12; 2-3 months old and weighing 25-30 kg) were subjected to thoracotomy. Segments (10 mm)of the mid left anterior descending coronary artery and left circumflex coronary artery were exposed and aseptically wrapped with a cotton mesh soaked with IL-1β (5 μg). After 2 weeks, the animals were anesthetized and quantitative coronary arteriography (QCA) was performed. The stenosis sites were randomized into three groups for stent insertion: a sirolimus-eluting stent (SES) group (FirebirdTM, n=7), a paclitaxel-eluting stent (PES) group (TAXUSTM, n=9), and a bare-metal stent (BMS) group (YINYITM, Dalian Yinyi Biomaterials Development Co., Ltd, China, n=8). The three different stents were randomly implanted into stenosis segments. Expression of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-α), P-selectin and vascular cell adhesion molecule-1 (VCAM-1) was determined by reverse transcription-coupled polymerase chain reaction (RT-PCR).Results QCA showed severe stenosis in IL-1β treated segments. The SES and PES groups showed lower 1-month angiographic late lumen loss (LLL) within the stent and the lesion compared with BMS (P 〈0.05) by follow-up QCA. The SES showed lower LLL than that of PES in reducing 1-month inflammation lesions in pigs by follow-up QCA ((0.15±0.06)mm vs. (0.33±0.01) mm, P 〈0.0001). The neointimal hyperplasia areas in SES and PES showed lower than those of BMS (SES (11.6±1.7) mm2, PES (27.2±1.6) mm2 vs. BMS (76.2±1.3) mm2, P 〈0.0001). The mRNA expression of MCP-1 by RT-PCR in SES and PES showed lower than that of BMS at 30 days after stenting (SES 0.20±0.03, PES 0.48±0.49 vs.BMS 0.58±0.07, P 〈0.05). Levels of VCAM-1 in SES were significantly lower than those of PES and BMS (SES 0.35±0.08 vs. PES 0.65±0.13, BMS 0.70±0.06, P 〈0.05). Histochemical immunostaining of vessel walls showed lower inflammatory chemokine MCP-1 expression in the SES and PES groups compared with BMS.Conclusion SESs were superior in reducing 1-month angiographic LLL in inflammation lesions in pigs, strongly suggesting that SESs can suppress inflammatory reactions in ISR at multiple points.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2010年第17期2405-2409,共5页 中华医学杂志(英文版)
关键词 INTERLEUKIN-1Β SIROLIMUS PACLITAXEL drug-eluting stent INFLAMMATION in-stent restenosis interleukin-1β sirolimus paclitaxel drug-eluting stent inflammation in-stent restenosis
  • 相关文献

参考文献23

  • 1Babapulle MN,Joseph L,Belisle P,Brophy JM,Eisenberg MJ.A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.Lancet 2004; 364:583-591.
  • 2Forrester JS,Fishbein M,Helfant R,Fagin J.A paradigm for restenosis based on cell biology:clues for the development of new preventive therapies.J Am Coll Cardiol 1991; 17:758-769.
  • 3Kornowski R,Hong MK,Tio FO,Bramwell O,Wu H,Leon MB.Instent restenosis:contributions of inflammatory responses and arterial injury to neointimal hyperplasia.J Am Coll Cardiol 1998; 31:224-230.
  • 4Welt FG,Rogers C.Inflammation and restenosis in the stent era.Arterioscler Thromb Vasc Biol 2002; 22:1769-1776.
  • 5Nuhrenberg TC,Voisard R,Fahlisch F,Rudelius M,Braun J,Gschwend J,et al.Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty.FASEB J 2005; 19:246-248.
  • 6Mause SF,von Hundelshausen P,Zernecke A,Koenen RR,Weber C.Platelet microparticles:a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium.Arterioscler Thromb Vasc Biol 2005; 25:1512-1518.
  • 7Morice MC,Colombo A,Meier B,Serruys P,Tamburino C,Guagliumi G,et al; REALITY Trial Investigators.Sirolimusvs paclitaxel-eluting stents in de novo coronary artery lesions.the REALITY trial:a randomized controlled trial.JAMA 2006;295:895-904.
  • 8Goy JJ,Stauffer JC,Siegenthaler M,Beno(i)t A,Seydoux C.A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology:The TAXi Trial.J Am Coll Cardiol 2005; 45:308-311.
  • 9Windecker S,Remondino A,Eberli FR,Jüni P,R(a)ber L,Wenaweser P,et al.Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.N Eng J Med 2005; 353:653-622.
  • 10Donners MM,Daemen MJ,Cleutjens KB,Heeneman S.Inflammation and restenosis:implication for therapy.Ann Med 2003; 35:523-553.

同被引文献16

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部